News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Signs Cancer Treatment Deal With Novartis AG; Immunogen to Receive $45 Million Upfront With Potential for $200 Million



10/11/2010 6:50:33 AM

ZURICH, Oct 11 (Reuters) - ImmunoGen Inc (IMGN.O) has signed a deal with Novartis (NOVN.VX) that lets the Swiss drugmaker develop anticancer treatments with fewer side effects, ImmunoGen said, giving the U.S. group another boost after recent positive data.

Read at Reuters
Read at Xconomy
Read at Wall Street Journal

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES